Avantium Technologies Announces Collaboration with GlaxoSmithKline
News Apr 21, 2006
Avantium Technologies have announced that they have a collaboration with GlaxoSmithKline for the extensive screening of several GSK pharmaceutical compounds utilizing Avantium’s high-throughput polymorph, salt and co-crystal screening capabilities to find novel solid forms.
Avantium Technologies is an innovation-based company and its unique integrated screening platform provides a fast and efficient way to explore a wide array of crystallization conditions to generate and identify novel solid forms.
“We welcome this great opportunity to collaborate with GlaxoSmithKline,” said Guus Scheefhals, Chief Business Officer of Avantium Technologies. “It is an honor to contribute to the development of GSK’s therapeutic products by using our highthroughput technology platform and rational experimental design strategy. This intensive partnership is a valuable recognition of our capabilities.“
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018